Kinarus Therapeutics Holding AG (XSWX:KNRS) ROC % : -460.69% (As of Dec. 2021)

View and export this data going back to 1999. Start your Free Trial

What is Kinarus Therapeutics Holding AG ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Kinarus Therapeutics Holding AG's annualized return on capital (ROC %) for the quarter that ended in Dec. 2021 was -460.69%.

As of today (2024-06-16), Kinarus Therapeutics Holding AG's WACC % is 0.00%. Kinarus Therapeutics Holding AG's ROC % is 0.00% (calculated using TTM income statement data). Kinarus Therapeutics Holding AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Kinarus Therapeutics Holding AG ROC % Historical Data

The historical data trend for Kinarus Therapeutics Holding AG's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kinarus Therapeutics Holding AG ROC % Chart

Kinarus Therapeutics Holding AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROC %

Get a 7-Day Free Trial

-14.91

-50.99

-64.46

-80.71

-872.34

Kinarus Therapeutics Holding AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
ROC %	Get a 7-Day Free Trial															-36.04	-102.02	-419.78	-493.40	-460.69

Kinarus Therapeutics Holding AG ROC % Calculation

Kinarus Therapeutics Holding AG's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:

	ROC % (A: Dec. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2020 )	+	Invested Capital (A: Dec. 2021 ))	/ count )
=	-0.41 * ( 1 - 0% )	/	( (0.073	+	0.021)	/ 2 )
=	-0.41	/	0.047
=	-872.34 %

where

	Invested Capital		(A: Dec. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.127	-	0.031	-	( 0.063	-	max(0, 0.104	-	0.127	+	0.063	))
=	0.073

	Invested Capital		(A: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.136	-	0.086	-	( 0.124	-	max(0, 0.107	-	0.136	+	0.124	))
=	0.021

Kinarus Therapeutics Holding AG's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2021 is calculated as:

	ROC % (Q: Dec. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2021 )	+	Invested Capital (Q: Dec. 2021 ))	/ count )
=	-0.334 * ( 1 - 0% )	/	( (0.124	+	0.021)	/ 2 )
=	-0.334	/	0.0725
=	-460.69 %

where

	Invested Capital		(Q: Jun. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.181	-	0.046	-	( 0.17	-	max(0, 0.17	-	0.181	+	0.17	))
=	0.124

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.136	-	0.086	-	( 0.124	-	max(0, 0.107	-	0.136	+	0.124	))
=	0.021

Note: The Operating Income data used here is two times the semi-annual (Dec. 2021) data.

Kinarus Therapeutics Holding AG (XSWX:KNRS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Kinarus Therapeutics Holding AG's WACC % is 0.00%. Kinarus Therapeutics Holding AG's ROC % is 0.00% (calculated using TTM income statement data). Kinarus Therapeutics Holding AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Kinarus Therapeutics Holding AG ROC % Related Terms

Thank you for viewing the detailed overview of Kinarus Therapeutics Holding AG's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kinarus Therapeutics Holding AG (XSWX:KNRS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Transportation » Kinarus Therapeutics Holding AG (XSWX:KNRS) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3, Avenue de Florimont, Lausanne, CHE, CH-1006

Website

https://www.perfect.aero

Perfect Holding SA is a Switzerland-based company that focuses on the acquisition and management of investments in companies, which are active in the aircraft management and related services sector. The company operates in one business segment which includes Charters. The products provided by the company include Aircraft sales, Charter sales, and Aircraft consultancy.

Kinarus Therapeutics Holding AG (XSWX:KNRS) Headlines

No Headlines